Schizophrenia Market Research Report: Information by
Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic
Schizophrenia and Undifferentiated Schizophrenia), Treatment {Second-Generation
Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa
(Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda
(Lurasidone)], Third-Generation Antipsychotics and others}, Route of
Administration (Oral and Injectables) and Region (Americas, Europe,
Asia-Pacific and Middle East & Africa) - Forecast till 2025
Market Highlights
The global Schizophrenia Market is expected to grow at a CAGR of 3.2% during the
forecast period 2017-2023.Schizophrenia is a chronic and severe mental disorder
that affects the thinking, feeling, and behavior of the person. People with
schizophrenia may be more in imagination world and lost touch with reality.
Although schizophrenia is not as common as other mental disorders, the symptoms
can be very disabling. The symptoms of this disease are categories in three way
that are positive, negative, and cognitive.
People with schizophrenia are
more prone to die earlier than the normal population. This is often due to
physical illnesses, such as cardiovascular, metabolic and infectious diseases.
According to WHO, in 2016, More than 50% of people with schizophrenia are not
receiving appropriate care. 90% of people with untreated schizophrenia live in
low and developing countries, such as India, Pakistan, etc.
Increasing prevalence of patients
seeking treatment and rising demand for improved healthcare infrastructure are
expected to drive the market. Moreover availability of funds and WHO initiative
towards developing countries fuel the market in developing region.
Regional Analysis
The Americas dominate the global
schizophrenia market owing to the presence of awareness of healthcare, high
healthcare spending, and increasing government support for research &
development.
Europe holds the second largest
share of the global schizophrenia market as result of increasing focus of
various government agencies on the treatment of mental illness disease such as
schizophrenia. Moreover, the growing public awareness about schizophrenia
likely to boost the Europe market.
Asia Pacific is the fastest
growing schizophrenia market across the globe. Moreover, rapidly developing
economy, increasing healthcare expenditure, and the government’s initiatives
for research & development projected to drive the market in India, Iran,
Pakistan, Tanzania, over the forecasted period. Additionally, WHO initiative
for training primary health-care personnel, providing access to essential
drugs, and supporting families in providing home care lead the market growth of
the schizophrenia in the region.
The Middle East and Africa holds
the least share of the global market due to limited availability of medical
facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle
East & African market.
Segmentation
The
global schizophrenia market is segmented on the basis of by diagnosis, by
treatment type, and by end user. On the basis of the diagnosis, it is segmented
into blood and urine tests, brain imaging, vision testing, and others. On the
basis of the treatment type, it is segmented into surgery, radiation therapy,
medications, and others. On the basis of the end user, it is segmented into
hospitals, clinics, diagnostic centers, rehabilitation centers and others.
Key
Players
Some of
key the players in the market are Minerva Neurosciences (U.S.), Promentis
Pharmaceuticals, Inc. (U.S.), Bristol-Myers Squibb (U.S.), PsychoGenics Inc.
(U.S.), Vineuro Pharmaceuticals, Novartis AG (Switzerland), Merz Pharma GmbH
& Co. KGaA (Germany), AbbVie Inc. (U.S.), Eli-Lilly and Company (U.S.),
AstraZeneca Plc (U.K)
No comments:
Post a Comment